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ABSTRACT
There is a new improvement in oncology nearly in every day as a result of preclinical or clinical. As the number of publication per capita, 
Turkey is far behind the other developed European countries. For example, the number of publications in oncology field is 2.134.964 in the 
world, it is 15.576 in our country. The most important obstacles for clinical trials in Turkey may be listed as financial problems, difficulties 
of working conditions, time limitation due to work intensity, inadequate experienced/trained man-power, absence of assistance team at all 
steps of a scientific trial, difficulties faced during project planning and ethics committee submissions, and lack of motivation. In this article, 
we, as young oncologists, aimed to discuss the place of Turkey in areas of scientific and clinical trials in the world; underlying causes for 
inadequate number, type and quality of national studies and possible solution proposals in our country.
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ÖZET
Genç Onkologların Bakış Açısı ile Türkiye’deki Klinik Araştırmalar: Engeller ve Çözüm Önerileri
Günümüzde onkoloji alanında her geçen gün deneysel ve klinik araştırmaların sonucu olarak yeni bir gelişme olmaktadır. Kişi başına 
düşen yayın sayısına bakıldığında, Türkiye diğer gelişmiş Avrupa ülkelerinden epeyce geride yer almaktadır. Örneğin tüm dünyada kanser 
alanında yapılmış olan yayınların sayısı 2,134,964 iken, Türkiye’dekilerin sayısının toplamı 15.576’dır ve toplam yayın sayısı nüfus oranları ile 
karşılaştırıldığında diğer gelişmiş Avrupa ülkelerine göre epeyce geride kalmaktadır. Türkiye’de klinik çalışmaların önündeki en önemli engel-
lerin finansal sorunlar, çalışma şartlarının zorlukları, iş yoğunluğu nedeniyle zaman kısıtlılığı, deneyimli-eğitimli insan gücü eksikliği, bilimsel 
çalışmanın tüm aşamalarında yardımcı olacak bir ekibin eksikliği, proje hazırlama ve etik kurul izin sürecinde yaşanan sıkıntılar, motivasyon 
eksikliği  olduğu düşünülebilir. Biz genç onkologlar olarak bu yazımızda; dünya genelinde ülkemizin bilimsel ve klinik araştırmalardaki yerini, 
bilimsel araştırmaların yapılamamasının nedenlerini, ülkemizde yapılmakta olan yayınların çeşit ve kalitesini, bizim ülkemize ait varolan ger-
çekleri ve bunlara yönelik getirilebilecek çözüm önerilerini tartışmayı amaçladık.
Anahtar kelimeler: Onkoloji, Klinik araştırmalar, Türkiye
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INTRODUCTION
In our era, not a single day passes without an new 
development in basic and clinical oncology every, 
secondary to increased momentum of production 
of new information.Thorough these researches that 
quality of our care for patients increases day by day, 
which translates into continuously increasing cure 
rates and survival figures for many types of cancer. In 
our globalization age where speed of communication 
is so fast, we have the chance to observe our country 
and the rest of the world and make comparisons. As 
a result we question our position in the world ever-
day. We believe we have 2 options: To continue to 
consume the knowledge generated elsewhere, or to 
become an active player in the field. Inquiring our-
selves with questions such as “Are there enough 
clinical trials conducted in our country?”, “What is 
the quality of the clinical trials conducted?”, “Why 
cannot we, oncologists, perform significant (practice 
changing) scientific researches?” and realizing our 
deficits led to the foundation of “Young Researchers 
Working Group (YRWG)”.  Our aim, as the YRWG, 
is to determine our current position and problems; to 
define what we can perform better under the existent 
conditions; and to improve our deficient aspects by 
continuing education in country or elsewhere. 
We, as young Turkish oncologists, want to contribute 
more both in quality and quantity to scintific knowl-
edge generated from our country. Turkish Oncology 
Group, founded in 1989 by leading oncologist in our 
country to promote multicenter and multidisciplinary 
nation-wide trials, hold yearly meetings to develop 
trials. At the latest one, we were given the opportunity 
to discuss the problems in researches in oncology as 
young oncologists by the organizing committee.
In the present article; we aimed to discuss the place 
of our country in the world; type and quality of na-
tional publications, realities of our country, underly-
ing causes and possible solution proposals through 
the young oncologist’s point of view.
Current Condition of Clinical Trials in Turkey 
and Comparison with other Countries
In 2011, Research and Development (R&D) expendi-
ture in the world was nearly 127 billion $, whereas 
Turkey had an R&D expenditure of 60 million $, 
which was 0.05% of the total budget. R&D trials are 
divided into basic researches and clinical researches. 
Exploration of new molecules, identification of the 
area of use for new molecules, and re-evaluation of 
a drug make-up of the basic researches, and clinical 
tests are performed in the clinical research part. To-
gether these two contribute to the process of drug de-
velopment with long duration and high cost.1 
Currently, it is accepted that R&D competence of a 
country is parallel with its clinical trial volume. In an 
assessment of year 2011, it was reported that United 
States of America (USA) and European community 
(EC) countries occupied the first line in number of 
clinical trials sponsored by the industry (Figure 1). 
In the same assessment, it was reported that Turkey 
was the 16th in pharmaceutical industry in the world, 
whereas it is at the 36th position when clinical trials 
were considered.1
Germany, France, United Kingdom, Spain, and Italy 
are the first five countries which value R&D, and they 
are defined as EC5. These countries are accepted to 
have strong indicators in the pharmaceutical indus-
try. USA and Japan are the other prominent countries 
after the EC5 countries. On the other hand, China, In-
dia, Russia, Brazil, and Turkey are considered among 
countries with recent development potentials, and 
these countries are defined as developing countries.1 
Number of scientific studies performed all over the 
world up until January 2014 is 157.252; whereas it 
is 6.528 among the Middle Eastern countries and in 
our country it is 1373 in Turkey. When we compare it 
with our current population, it is observed that Turkey 
is far behind the world (Figure 2).1 
When publications related to cancer were reviewed, 
it was found that 2.947 (5.1%) out of 57.380 publi-
cations; 1.297 titles (2.2%), and 1.345 (2.3%) key 
words were originated from Turkey. A search per-
formed by “Pubmed” as the basic search engine in-
dicated that there were 2.134.964 articles published 
in cancer field in the world, whereas the number of 
articles from Turkey was (cancer[MeSH Major Top-
ic]) AND turkey [Affiliation]  15.576. Similarly, ac-
cording to year 2012 data, total of articles published 
was 1.258; and when the number was compared with 
population ratio, it was observed that Turkey was far 
behind the developed European countries such as 
Germany, France, and Italy. The number of publica-
tions per million people is 16.77 in Turkey; 69.59 in 
USA, 69.50 in Greece, 71.0 in Italy, 82.88 in France 
and Israel. In the year 2012, case reports formed the 
majority of publications from Turkey; and numbers 
of publications related to randomized clinical trials, 
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clinical controlled trials, and especially phase studies 
were far behind the publications in the world (Table 
1).2 
Difficulties in Conducting a Clinical Trial in Tur-
key
Conducting a clinical trial in Turkey generally has 
many diffculties.3 The way the current global health-
care system works, which has been founded on “capi-
tal and service”, places routine occupational works in 
the center of our profession. And this affects equally 
physicians working at different health care systems: 
University hospital, Training and Research hospital 
and Governmental hospital. Some physicians are are 
both clinicians and scientist who are trying to conduct 
clinical research. For the most clinician-scientists in 
oncology, there is an extreme imbalance in favor 
of routine work. It is generally seen that research is 
something to be done in spare time or after the work 
hours.
Some of the problems may be listed as follows: Al-
most no time left from the daily routine; incomplete 
recording of patient data because of strenuous condi-
Figure 1. Numbers of sponsored clinical trials by the in-
dustry, 2011*(adapted from www.clinicaltrials.gov.tr) (Ac-
cess date: 19/02/2014).
Figure 2. Regional distribution of all ongoing trials in the world, 2014* (adapted from www.clinicaltrials.gov.tr) (Access date: 
19/02/2014).
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tions at work, lack of a team, which would help at all 
steps of a clinical trial (data collection, data analysis, 
patient follow up, screening of medical files etc.), 
too-long approval processes, suspension of many 
projects in some centers because of inadequate num-
ber of patients, financial difficulties, and lack of mo-
tivation.4,5,6 
The most important obstacle to tackle with is the 
lack of effective scientific politics. Although there 
is the Ministry of Science, Industry, and Technology 
in our country, there is no effective science politics 
yet. Existent legal regulations may be another bar-
rier against performing trials. For example, in an in-
vestigator initiated trial, investigator has to find the 
money for standard drugs which are re-imbursed in 
daily practice. In reality, no other organization than a 
pharmaceutical company tends to pay for the clinical 
trial expenditure. Pharmaceutical companies natural-
ly tend to support trials which are in line their future 
perspectives. 
Another problem is the shortage of experienced and 
trained man-power. Clinical trial methodology is not 
the natural part of training in oncology in our coun-
try. Although there are sufficient number of cases and 
infrastructure in oncology field, numbers of investi-
gating physicians, and assisting personnel in clinical 
trials are not sufficient.
Another important problem is the lack of financial 
support in performing clinical trials. Although there 
are financial supports that can be received from “TU-
BITAK”, Scientific Research Projects (SRPs) incor-
porated in universities, and from societies; selectivity 
and difficulty in reaching those supports as well as 
small sizes of budgets do not help to solve the prob-
lem. Usually, researchers try to reach required materi-
als for clinical trials (kits, experimental animal etc.) 
by their own means. 
Project writing and difficulties at ethics committee 
approvals also decrease the motivation to perform 
scientific researches. According to effective regu-
lations about clinical trials, especially phase II and 
III trials can be initiated after tiring approval steps. 
These are the most important drawbacks for conduc-
tion of prospective interventional trial, which is being 
coordinated by a Turkish center. Although sponsor 
or financial source is found, approval of regulatory 
authority takes too long. Even clinical trial depart-
ments of large pharmaceutical companies can not 
pass through the approval process in a timely manner. 
It is not unusual that a trial recruits the total number 
of patients abroad until ethics committee approval is 
attained in our country. It sometimes seems to us as 
researchers that members of ethics committees try 
to find the hidden doctor Frankenstein in the clinical 
trial: “They mut have been doing something unethical 
and I have to find it.” As ethics committees have start-
ed to function in 2000s in Turkey, clinical trials have 
become safer and better designed for both researcher 
and volunteer aspects.7 However, this favorable con-
dition has not relieved financial problems in phase II/
III trials. 
Table 1. Types and numbers of publications from Turkey, 2012*
Type of Manuscripts Turkey Worldwide %
Total 14 288  1 154 537 
Case report 6 594 219 454 19.0
Review 1 018  181 878 15.7
Comparative research 1 327 91 576 7.9
Randomized, controlled 271  22 064 1.91
Controlled, clinical  94  4 811 0.4
Multicentric 119  25 511 2.2
Phase I 4  8 046  
Phase II 51 14 500 
Phase III 3  3 730  
Phase IV 3 77 
Systematic review 70  22 879 
Meta-analyses 16  6 228  
Guideline  4  2 535  
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One of the other important problems is difficult work-
ing conditions, and intensity of work. Weekly work-
ing hours of Turkish healthcare service personnel are 
longer than their European colleagues, which limits 
time to be spared for clinical trial conduction. Num-
ber of researchers and academic personnel per univer-
sity are decreased by increasing number of medical 
schools. Many clinician researchers have to care for 
significant number of patients in a day in order to be 
paid enough in our current health care policy system. 
The other reason for being too-busy with the patients 
in the medical oncology is the insufficient number of 
medical oncologist in our country currently. It is just 
over 400 hundred including fellows in training. Un-
der such circumstances, academic personnel are not 
able to spare enough time for clinical trials when they 
have responsibilities in student and researcher train-
ing programs, administrative duties, and healthcare 
services like examination and performing surgery. 
When all drawbacks are considered together, it is ob-
vious that a physician, who calls himself a researcher, 
will feel burned out because of his/her workload at 
the hospital, ethics committee procedures, provision 
of financial sources, missing data, differences in tech-
nical facilities between the affiliations, lack of plural-
ist participation and team-work, and lack of commu-
nication and dynamism in teamwork. These factors 
may cause motivation loss in scientists who would 
like to become researchers.
Solution Proposals to Increase the Number of 
Clinical Trials in Turkey
Time: One of the most important causes that prevent 
conduction of clinical trials in Turkey is that physi-
cians’ heavy workload of routine healthcare respon-
sibilities and that they should spend all of their daily 
work-time on patient care. Physicians should allocate 
from their spare time to plan and conduct clinical tri-
als. Knowledge and energy of physicians should not 
be only used to escalate routine day-work in hospi-
tals. During or after subspecialty training programs, 
certain work-days should be spared for physicians 
to encourage conducting clinical trials with actual 
values within their weekly programs. If such a re-
organization is performed, physicians will orientate 
to perform high quality scientific studies without sac-
rificing their personal lives. Thus, studies with high 
scientific quality will be published, and new contribu-
tions to the literature will be made.
Knowledge and Facilities: Production of knowledge 
is both an obligation to survive and to compete in life 
and, from a population perspective, a debt to contrib-
ute in modern civilization. It is obvious that civili-
zation horizons like social, economic, and humanity 
levels of populations, which can produce and sustain 
production of knowledge, are brilliant.
Scientific studies in oncology can be classified as ba-
sic, translational and clinical studies. Clinical stud-
ies in oncology form the basis where oncologist can 
generate new information in diagnosis, treatment, 
and follow up. Unfortunately, there are quite a few 
scientific studies from Turkey, which may be called 
practice-changing. One of the reasons may be lack of 
expertise and facilities.
A clinical trial is a scientific process, which starts 
with a question asked to resolve an important health 
problem; in which solutions are searched according 
to some principles, tests for hypothesis is built and 
results are interpreted by humans, and from which 
finally a decision is extracted. Therefore, the most 
important factor in a clinical trial is human. Individu-
als with problems (patients), clinical scientists to ask 
important questions, statisticians to determine meth-
ods, ethics committees and regulatory authorities, 
clinicians testing hypotheses, assisting nurses during 
the testing period, clinical study coordinators, and 
financial resources to cover them all are required to 
conduct a clinical trial.
Currently, expectations of academic structure and 
regulatory authorities from clinicians with academic 
qualifications working at universities are patient-care 
centered. Actually, the origin of word “university” is 
“universitas magistrorum et scholarium” (community 
of masters and scholars),8 and it indicates what the 
current expectations should focus. In our opinion, 
academic staff should be divided as research oriented 
patient-care oriented, and training-oriented, so that 
the efficiency can be increased by taking an action 
from a different point of view. What we propose to 
expect from research-oriented clinical scientists is 
that they develop hypotheses about existent clinical 
problems, and prepare suitable testing environments 
for them while they are continuing their daily prac-
tices in a specific field of oncology. We believe that 
these three groups of clinicians will have very impor-
tant duties in planning and conducting clinical trials 
in collaboration, and it will be much easier to reach 
the common target.
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Clinicians should be perceived as team members to 
conduct a clinical trial, and future scientists. They 
should be trained in patient enrollment in the clinical 
trial, patient follow up, and in general and/or specific 
rules of clinical trials to manage protocol compliance 
of the study. International and national training op-
portunities should be created for clinicians interested 
in clinical trials, and they should be encouraged to 
attend them, and also certifications should be regu-
larly performed. Among these clinicians, candidates 
for academic staff or ones with academic positions 
should be directed to one of the 3 main divisions ac-
cording to their interests and desires.
Expecting their contributions in translational or clini-
cal trials, young clinicians should be encouraged 
to attend doctoral program or laboratory projects 
abroad, and these young clinicians should be entitled 
to research teams. 
Starting from senior assistant physicians, who are 
having their subspecialty training in medical oncolo-
gy field, project contests including how a question for 
a clinical trial is asked and ending up model clinical 
projects with real-life outcomes may be organized.
Positions for clinical trial assistance (nurse, center co-
ordinator, medical secretary, computer programmer 
etc.) other than the physician should be identified, 
and certificated training programs should be prepared 
for them. 
Collaboration: When the working hours in Turkey 
are compared especially with the ones in European 
and North American countries, ours are quite long 
and numbers of patients contacted in a day are higher, 
which causes shortage of time for studies and also de-
creased body and mental performances, so it is quite 
difficult to conduct scientific researches. Moreover, 
as we all know, there are many steps starting from 
designing to publication in performing clinical trials. 
It is usually difficult for every researcher to manage 
all of these by him-/herself. During collaborative 
works, time and energy are saved by task divisions, 
and the saved portions are transferred to increase the 
performances. In collaborative studies, all details are 
shared by brain-storming. The topics are analyzed. 
Every team member has his/her target, level of capa-
bility, and attitude to work. In collaborative studies, 
tasks are divided, and all details are considered and 
evaluated. Participants work more eagerly because of 
his/her responsibilities to both him-/herself and the 
team members. He/she is motivated. When the study 
reaches its target, self-esteems of participants are in-
creased. The same things are valid also for retrospec-
tive studies. Cases from a single center generally do 
not have very strong data, which may increase the 
interest on international platforms. However, multi-
center trials are more powerful statistically, and are 
more significant. Additionally, real existence in in-
ternational platforms require strength, which is only 
possible if our publication quality is increased, and if 
we work collaboratively.
Finance and Regulations: Many developed and de-
veloping countries have focused on pharmaceutical 
industry at least 10 years ago, and they stood out in 
the competition. They drew important investments, 
which would enable them to become importing coun-
tries.  Turkey is behind especially BRIC countries 
(Brazil, Russia, India, and China) in drawing these 
investments. In Turkey, total clinical trial budget is 
60 million $, and 80% of it is sponsored by global 
pharmaceutical firms.1 However, in order to reach a 
competitive level with other countries in clinical tri-
als, the infrastructure and regulatory (related laws and 
regulations) issues should be solved by the Turkish 
government.
To achieve this goal, clinical trials being conducted in 
Turkey should be announced, and also importance of 
clinical trials should be described. Additionally;
1. Research know-how and researcher’s motivation 
(researchers receive at most 30% of the “investiga-
tor’s payment”. This ratio is 17% in training and re-
search hospitals) should be improved in universities, 
training and research hospitals, and governmental 
hospital (research rooms, research nurses, financial 
systems), 
2. Providing financial resources for R&D,
3. The government should provide a stable environ-
ment economically as well as by releasing competent 
regulations with the European Union to draw global 
investments, 
4. Providing tax advantage for international investors 
for R&D, and supporting investments of manufac-
ture,
5. Establishing collaborations between universities 
and the industry, and providing participation of sup-
porting affiliations in scientific meetings are impor-
tant.1 
Working with the Mentor: Training programs, in 
forms of seminars and courses, have been held in 
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Turkey for clinical trials since 2003. They were con-
sistent with the standards of European Union. Semi-
nars have been organized about important topics in 
study protocols and clinical research methodology, 
and clinical study applications under the supervi-
sions of mentors.6 One of the most important criteria 
in designing and organization of a study is the men-
tor, responsible investigator. Mentor can be defined 
as an advisor, consultant, or guide. In other countries, 
mentors design study conditions appropriately for 
the study, and they are paid for their services. They 
are encouraged for clinical trials elsewhere, but men-
tors work volunteering with an extra performance in 
Turkey. It is hard to define an academic person for 
this position in Turkey, because the position is com-
pletely volunteer-based without additional payment, 
and there is intense patient load for academic people 
every day. 
The most crucial step to overcome the obstacle is to 
eliminate the volunteer-based approach, and to add 
the time into daily working hours for encouragement. 
CONCLUSION
Contribution in science should be the common inten-
tion of all academic society. Increasing the number 
and quality of scientific researches is important. De-
spite all problems and obstacles, increasing the num-
ber of scientific researches performed individually or 
collaboratively will re-establish the supply-demand 
equilibrium. It may be expected that governmental 
authority follows an approach which may solve ex-
istent problems to compete with rapid improvements 
in dynamic scientific fields like oncology. For the 
fulfillment of this expectation, scientists and support-
ers of R&D studies must apply a continuous pressure 
governmental authority to ease the difficulties of con-
ducting a trial.
In conclusion, it is believed that scientists, supporters 
for R&D, and governmental authorities should work 
collaboratively and consistently to increase the num-
ber and quality of studies in oncology in Turkey so 
that they can include international phase II/III stud-
ies. As a knowledge-consumer country, our ultimate 
goal must be “an active player in the field” not only in 
oncology but in every field in science.
REFERENCES
1.  Turkey Pharmaceutical Sector Vision 2023 Report Strategy 
Document. http://www.aifd.org.tr/PDF/2023_Rapor/2023_
strat_en.pdf (Access date: 19/02/2014).
2.  Sencan O. Evaluation of Clinical trials that are conducted and 
published in Turkey. 9th National Oncological Researches 
Work-shop, November 20-24, 2013. Antalya, Turkey.
3.  Akan H. Clinical research in Turkey. Turk J Hematol 24: 1-3, 
2007.
4.  Ilbars H, Yazgan S, Dagistanli S. Drug trials in Turkey (Turkish). 
GCP Journal (IKU) 7: 3-9, 2004.
5.  Kansu E, Akbas O, Hayran M, et al. Clinical scientific research 
potentials in Turkey. The Monitor 6: 51-54, 2006.
6.  Aydin E. Regulations governing drug trials in Turkey. Med Law 
22: 95-103, 2003.
7.  http://www.etymonline.com/index.php?term=university (Ac-
cess date: 19/02/2014).
Correspondence
Dr. Tulay AKMAN
Tepecik Egitim ve Arastirma Hastanesi
Tibbi Onkoloji Bolumu
Gaziler Caddesi, No: 468
Yenisehir, IZMIR / TURKEY
Tel: (+90.232) 444 35 60
Fax: (+90.232) 433 07 56
e-mail: tulaytuzel@gmail.com
